ERCC1基因多态性在胃癌中的研究

摘要/Abstract

摘要：作为核酸损伤修复过程的重要成员，切除修复交叉互补基因1（ERCC1）的表达情况与胃癌的发生发展密切相关。研究发现，ERCC1基因的多态性会改变该基因自身的表达，并对铂类化疗药物的敏感性和疗效产生影响，通过对基因多态性的检测可以指导胃癌患者的个体化化疗。

田源,单泽志,彭佳远,汪昱. ERCC1基因多态性在胃癌中的研究[J]. 国际肿瘤学杂志, 2014, 41(8): 666-668.

Tian Yuan, Shan Zezhi, Peng Jiayuan, Wang Yu. ERCC1 gene polymorphism in gastric cancer[J]. Journal of International Oncology, 2014, 41(8): 666-668.

［1］ Proserpio I, Rausei S, Barzaghi S, et al. Multimodal treatment of gastric cancer［J］. World J Gastrointest Surg, 2014, 6(4): 55-58. ［2］ Zaanan A, Dalban C, Emile JF, et al. ERCC1, XRCC1 and GSTP1 single nucleotide polymorphisms and survival of patients with colon cancer receiving oxaliplatinbased adjuvant chemotherapy［J］. J Cancer, 2014, 5(6): 425-432. ［3］ Cui S, Jiang L. Current translational tesearch status of ERCC1 expression of nonsmall cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2014, 17(5): 428-432. ［4］ Kirschner K, Melton DW. Multiple roles of the ERCC1XPF endonuclease in DNA repair and resistance to anticancer drugs［J］. Anticancer Res, 2010, 30(9): 3223-3232. ［5］ Yin M, Yan J, Martinez BE, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatinbased chemotherapies in gastric and colorectal cancer: a systemic review and metaanalysis［J］. Clin Cancer Res, 2011, 17(6): 1632-1640. ［6］ Squires MH, Fisher SB, Fisher KE, et al. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma［J］. Cancer, 2013, 119(17): 3242-3250. ［7］ Wang J, Zhou XQ, Li JY, et al. Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer［J］. Chin J Cancer Res, 2014, 26(3): 323-330. ［8］ Yamada Y, Boku N, Nishina T, et al. Impact of excision repair crosscomplementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912［J］. Ann Oncol, 2013, 24(10): 2560-2565. ［9］周倩茹, 邱红, 胡广原, 等. ERCC1和FGFR2在胃癌组织中的表达及其临床意义［J］. 肿瘤防治研究, 2012, 39(11): 1344-1348. ［10］ Doecke J, Zhao ZZ, Pandeya N, et al. Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma［J］. Int J Cancer, 2008, 123(1): 174-180. ［11］ Hou R, Liu Y, Feng Y, et al. Association of single nucleotide polymorphisms of ERCC1 and XPF with colorectal cancer risk and interaction with tobacco use［J］. Gene, 2014, 548(1): 1-5. ［12］ Li HY, Ge X, Huang GM, et al. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatinbased adjuvant chemotherapy in colorectal cancer in Chinese population［J］. Asian Pac J Cancer Prev, 2012, 13(7): 3465-3469. ［13］ Mazzoni F, Cecere FL, Meoni G, et al. Phase Ⅱ trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced nonsmallcell lung cancer［J］. Lung Cancer, 2013, 82(2): 288-293. ［14］ Sakano S, Ogawa S, Yamamoto Y, et al. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy［J］. Mol Clin Oncol, 2013, 1(3): 403-410. ［15］李师怡, 陈刚, 林贤东, 等. ERCC1基因多态性与胃癌发生发展的关系［J］. 中国肿瘤临床, 2012, 39(13): 907-910. ［16］ Lordick F, Kang YK, Chung HC, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, openlabel phase 3 trial［J］. Lancet Oncol, 2013, 14(6): 490-499. ［17］ Lo Nigro C, Monteverde M, Riba M, et al. Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer［J］. Int J Oncol, 2010, 37(5): 1219-1228. ［18］ Park SR, Kong SY, Nam BH, et al. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S1 plus cisplatin in metastatic gastric cancer patients［J］. Br J Cancer, 2011, 104(7): 1126-1134. ［19］ Rumiato E, Cavallin F, Boldrin E, et al. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5FUbased neoadjuvant therapy［J］. Pharmacogenet Genomics, 2013, 23(11): 597-604. ［20］ Li J, Zuo X, Lv X, et al. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population［J］. Tumour Biol, 2014, 35(8): 7569-7574.

[1]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	解淑萍, 孙亚红, 汪超.早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[4]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[5]	邵慧芳, 王学红, 芦永福.CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[6]	朱思雨, 王学红, 李文茜, 刘曙.胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[7]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平.GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[8]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳.沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[9]	姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文.血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.
[10]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻.胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[11]	杨俊, 李荣, 曾建昌.复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.
[12]	邓莉莉, 段星宇, 李保中.HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[13]	李佳宜, 王跃, 尚兰兰, 徐兴, 赵岩.人工智能技术在胃癌诊断与治疗中的实践与展望[J]. 国际肿瘤学杂志, 2023, 50(11): 677-682.
[14]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅.靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.
[15]	李立立, 安有志, 王艳军.替雷利珠单抗治疗MSI-H局部晚期胃癌患者1例[J]. 国际肿瘤学杂志, 2022, 49(7): 444-446.

ERCC1基因多态性在胃癌中的研究

ERCC1 gene polymorphism in gastric cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价